BR112022017048A2 - Anticorpos contra sars-cov-2 e métodos para usar os mesmos - Google Patents
Anticorpos contra sars-cov-2 e métodos para usar os mesmosInfo
- Publication number
- BR112022017048A2 BR112022017048A2 BR112022017048A BR112022017048A BR112022017048A2 BR 112022017048 A2 BR112022017048 A2 BR 112022017048A2 BR 112022017048 A BR112022017048 A BR 112022017048A BR 112022017048 A BR112022017048 A BR 112022017048A BR 112022017048 A2 BR112022017048 A2 BR 112022017048A2
- Authority
- BR
- Brazil
- Prior art keywords
- cov
- methods
- antigen
- sars
- antibodies against
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 4
- 102000036639 antigens Human genes 0.000 abstract 4
- 108091007433 antigens Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 208000025721 COVID-19 Diseases 0.000 abstract 2
- 208000037847 SARS-CoV-2-infection Diseases 0.000 abstract 2
- 239000013598 vector Substances 0.000 abstract 2
- 241001678559 COVID-19 virus Species 0.000 abstract 1
- -1 host cells Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Abstract
ANTICORPOS CONTRA SARSCOV-2 E MÉTODOS PARA USAR OS MESMOS. A presente revelação prove anticorpos e fragmentos de ligação a antígeno do mesmo que podem se ligar a um antígeno de SARS-CoV-2 e, em determinadas modalidades, têm capacidade de neutralizar uma infecção por SARS-CoV-2. Também são providos polinucleotídeos que codificam um anticorpo ou fragmento de ligação a antígeno, vetores e células hospedeiras que compreendem um polinucleotídeo, composições farmacêuticas e métodos para usar os anticorpos atualmente revelados, fragmentos de ligação a antígeno, polinucleotídeos, vetores, células hospedeiras e composições para tratar ou diagnosticar uma infecção por SARS-CoV-2.
Applications Claiming Priority (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062981984P | 2020-02-26 | 2020-02-26 | |
US202062982661P | 2020-02-27 | 2020-02-27 | |
US202062987298P | 2020-03-09 | 2020-03-09 | |
US202062989522P | 2020-03-13 | 2020-03-13 | |
US202062990369P | 2020-03-16 | 2020-03-16 | |
US202062992082P | 2020-03-19 | 2020-03-19 | |
US202062994235P | 2020-03-24 | 2020-03-24 | |
US202063001204P | 2020-03-27 | 2020-03-27 | |
US202063003214P | 2020-03-31 | 2020-03-31 | |
US202063005206P | 2020-04-03 | 2020-04-03 | |
US202063010589P | 2020-04-15 | 2020-04-15 | |
US202063011971P | 2020-04-17 | 2020-04-17 | |
US202063014024P | 2020-04-22 | 2020-04-22 | |
US202063023788P | 2020-05-12 | 2020-05-12 | |
US202063025133P | 2020-05-14 | 2020-05-14 | |
US202063039813P | 2020-06-16 | 2020-06-16 | |
US202063043653P | 2020-06-24 | 2020-06-24 | |
US202063050331P | 2020-07-10 | 2020-07-10 | |
US202063052810P | 2020-07-16 | 2020-07-16 | |
PCT/US2021/019531 WO2021173753A1 (en) | 2020-02-26 | 2021-02-25 | Antibodies against sars-cov-2 and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022017048A2 true BR112022017048A2 (pt) | 2022-11-16 |
Family
ID=74758682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022017048A BR112022017048A2 (pt) | 2020-02-26 | 2021-02-25 | Anticorpos contra sars-cov-2 e métodos para usar os mesmos |
Country Status (25)
Country | Link |
---|---|
US (3) | US11168128B2 (pt) |
EP (2) | EP4245373A3 (pt) |
JP (2) | JP7275405B2 (pt) |
KR (1) | KR20220164465A (pt) |
AU (2) | AU2021227687B2 (pt) |
BR (1) | BR112022017048A2 (pt) |
CA (1) | CA3158752C (pt) |
CL (1) | CL2022002335A1 (pt) |
CO (1) | CO2022013525A2 (pt) |
DK (1) | DK3872091T3 (pt) |
ES (1) | ES2954629T3 (pt) |
FI (1) | FI3872091T3 (pt) |
HR (1) | HRP20231031T1 (pt) |
HU (1) | HUE062777T2 (pt) |
IL (1) | IL295801A (pt) |
LT (1) | LT3872091T (pt) |
MA (1) | MA56074B1 (pt) |
MX (1) | MX2022010537A (pt) |
PL (1) | PL3872091T3 (pt) |
PT (1) | PT3872091T (pt) |
RS (1) | RS64645B1 (pt) |
SG (1) | SG11202110145SA (pt) |
SI (1) | SI3872091T1 (pt) |
TW (1) | TW202146442A (pt) |
WO (1) | WO2021173753A1 (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11680101B2 (en) | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
PT4045533T (pt) * | 2020-03-26 | 2024-02-14 | Univ Vanderbilt | Anticorpos monoclonais humanos para síndrome respiratória aguda grave coronavírus 2 (sars-cov-2) |
AU2020340881A1 (en) | 2020-04-02 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments |
EP4132579A1 (en) | 2020-04-10 | 2023-02-15 | Invivyd, Inc. | Compounds specific to coronavirus s protein and uses thereof |
TW202207983A (zh) * | 2020-06-12 | 2022-03-01 | 美商維爾生物科技股份有限公司 | 用於sars-cov-2感染的抗體療法 |
AU2021306709A1 (en) * | 2020-07-06 | 2023-02-09 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting SARS-CoV-2 |
WO2022054068A1 (en) * | 2020-09-14 | 2022-03-17 | Ramot At Tel-Aviv University Ltd. | Antibodies for the prevention, treatment and detection of coronavirus infection |
CN116157685A (zh) * | 2020-09-22 | 2023-05-23 | 贝克顿·迪金森公司 | 用于检测样品中抗体的基于细胞的分析 |
EP4228697A1 (en) | 2020-10-16 | 2023-08-23 | Invisishield Technologies Ltd. | Compositions for preventing or treating viral and other microbial infections |
US20220184125A1 (en) * | 2020-12-15 | 2022-06-16 | Rutgers, The State University Of New Jersey | S309 chimeric antigen receptors and methods of use |
WO2023001736A1 (en) | 2021-07-19 | 2023-01-26 | Universität Für Bodenkultur Wien | ENGINEERED ANTI-SARS COV-2 IgG3 ANTIBODIES |
WO2023034871A1 (en) * | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | High concentration antibody therapies for sars-cov-2 infection |
CA3230613A1 (en) * | 2021-09-01 | 2023-03-09 | Daren J. AUSTIN | Antibody therapies for sars-cov-2 infection in pediatric subjects |
WO2023039442A1 (en) * | 2021-09-08 | 2023-03-16 | Vir Biotechnology, Inc. | Broadly neutralizing antibody combination therapies for sars-cov-2 infection |
WO2023039540A2 (en) * | 2021-09-10 | 2023-03-16 | Jacobs Technion-Cornell Institute | Compositions and methods for determining humoral immune responses against seasonal coronaviruses and predicting efficiency of sars-cov-2 spike targeting, covid-19 disease severity, and providing interventions |
WO2023044397A1 (en) * | 2021-09-15 | 2023-03-23 | The Board Of The Trustees Of The University Of Illinois | Engineered receptors and monoclonal antibodies for coronaviruses and uses thereof |
WO2023046057A1 (zh) * | 2021-09-24 | 2023-03-30 | 南京金斯瑞生物科技有限公司 | 抗SARS-CoV-2 L452R刺突蛋白的单克隆抗体及其应用 |
WO2023086827A1 (en) * | 2021-11-09 | 2023-05-19 | Rhode Island Hospital | Predicting covid-19 antibodies among survivors with deep rna sequencing |
WO2023086635A1 (en) | 2021-11-15 | 2023-05-19 | Vir Biotechnology, Inc. | Virological and molecular surrogates of response to sars-cov-2 neutralizing antibody sotrovimab |
WO2023094980A1 (en) * | 2021-11-23 | 2023-06-01 | Fondazione Toscana Life Sciences | Antibodies to coronavirus |
CN114107223B (zh) * | 2021-11-25 | 2024-03-26 | 湖北省疾病预防控制中心(湖北省预防医学科学院) | 利用TPCK胰酶提高SARS-CoV-2病毒细胞培养滴度的方法 |
WO2023122211A2 (en) * | 2021-12-21 | 2023-06-29 | Duke University | Coronavirus antibodies and uses thereof |
WO2023130123A2 (en) * | 2022-01-03 | 2023-07-06 | Twist Bioscience Corporation | Bispecific sars-cov-2 antibodies and methods of use |
WO2023133509A2 (en) * | 2022-01-08 | 2023-07-13 | Carogen Corporation | Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection |
CN116444656B (zh) * | 2022-01-10 | 2023-09-22 | 东莞市朋志生物科技有限公司 | 一种鉴别新冠突变型抗原的抗体、试剂及方法 |
WO2023147251A1 (en) * | 2022-01-26 | 2023-08-03 | Academia Sinica | Antibody specific to coronaviruses and uses thereof |
WO2023150307A2 (en) * | 2022-02-03 | 2023-08-10 | Abpro Corporation | Compositions and methods against a virus |
WO2023201256A1 (en) * | 2022-04-12 | 2023-10-19 | Vir Biotechnology, Inc. | High dose antibody therapies for sars-cov-2 infection |
US20230357366A1 (en) | 2022-05-06 | 2023-11-09 | Generate Biomedicines, Inc. | Antigen Binding Molecules Targeting SARS-CoV-2 |
WO2023224714A1 (en) * | 2022-05-16 | 2023-11-23 | Lawrence Livermore National Security, Llc | Repaired therapeutic and prophylactic antibodies against sars-cov-2 variants |
KR20240008997A (ko) * | 2022-07-12 | 2024-01-22 | (재) 스크립스코리아항체연구원 | 사스-코로나 바이러스 2 중화 항체 |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、2官能性F(ab’)2抗体の産生のための使用 |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
CA2385347C (en) | 1999-10-04 | 2009-12-15 | Medicago Inc. | Method for regulating transcription of foreign genes |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
AU2003272511A1 (en) | 2002-09-13 | 2004-04-30 | Dyax Corporation | Cd44-binding ligands |
WO2004076677A2 (en) | 2003-02-26 | 2004-09-10 | Institute For Research In Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
KR20060020610A (ko) | 2003-04-08 | 2006-03-06 | 코로노바티브 비.브이. | 사스 |
WO2005012360A2 (en) | 2003-07-22 | 2005-02-10 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
EP1644414B1 (en) | 2003-07-22 | 2015-01-14 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
US7396914B2 (en) | 2003-08-04 | 2008-07-08 | University Of Massachusetts | SARS nucleic acids, proteins, antibodies, and uses thereof |
EP1676862B1 (en) | 2003-09-24 | 2010-12-22 | Kyowa Hakko Kirin Co., Ltd. | Recombinant antibody against human insulin-like growth factor |
US7750123B2 (en) | 2003-11-25 | 2010-07-06 | Dana Farber Cancer Institute, Inc. | Antibodies against SARS-CoV and methods of use thereof |
US7553944B2 (en) | 2004-07-21 | 2009-06-30 | The University Of Hong Kong | Human virus causing respiratory tract infection and uses thereof |
KR101255861B1 (ko) | 2004-11-11 | 2013-04-17 | 크루셀 홀란드 비.브이. | 사스-코로나바이러스에 대한 조성물 및 그것의 용도 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
JP2009537143A (ja) | 2006-05-19 | 2009-10-29 | アムゲン インコーポレイティッド | Sarsコロナウイルスに対する抗体 |
LT2511301T (lt) | 2006-08-04 | 2018-04-10 | Medimmune Limited | Žmogaus antikūnas prieš erbb2 |
WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
CN101679513A (zh) | 2007-03-06 | 2010-03-24 | 西福根有限公司 | 用于治疗呼吸道合胞病毒感染的重组抗体 |
EP2242768A4 (en) | 2008-01-17 | 2012-03-14 | Humabs Llc | CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION |
WO2009097133A2 (en) | 2008-01-30 | 2009-08-06 | Monsanto Technology, Llc | Transgenic plants with enhanced agronomic traits |
EP2408816B1 (en) | 2009-03-20 | 2019-09-04 | Amgen Inc. | Alpha-4-beta-7 heterodimer specific antagonist antibody |
CA2780221A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
HUE037159T2 (hu) | 2009-11-24 | 2018-08-28 | Medimmune Ltd | Targetált kötõdõ ágensek B7-H1 ellen |
JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
KR101299753B1 (ko) | 2010-11-19 | 2013-08-23 | 주식회사 단바이오텍 | 소 코로나바이러스 항원 결정기를 포함하는 스파이크 재조합 단백질 및 이에 대한 항체 |
AU2013209492B2 (en) | 2012-01-20 | 2018-02-08 | Genzyme Corporation | Anti-CXCR3 antibodies |
AR090244A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Formulacion de anticuerpo anti-selectina p |
US9803209B2 (en) | 2012-05-18 | 2017-10-31 | Novozymes A/S | Bacterial mutants with improved transformation efficiency |
TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗-egfr抗體及其用途 |
RU2016129959A (ru) | 2013-12-30 | 2018-02-02 | Эпимаб Биотерепьютикс Инк. | Иммуноглобулин с тандемным расположением fab-фрагментов и его применение |
JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
UY36245A (es) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
WO2016073879A2 (en) | 2014-11-06 | 2016-05-12 | Scholar Rock, Inc. | Transforming growth factor-related antibodies and uses thereof |
TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
KR20170140180A (ko) | 2015-02-24 | 2017-12-20 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 중동 호흡기 증후군 코로나 바이러스 면역원, 항체 및 그 용도 |
UA126270C2 (uk) | 2015-04-10 | 2022-09-14 | Емджен Інк. | Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин |
JP2018516879A (ja) | 2015-05-08 | 2018-06-28 | ユーリカ セラピューティックス, インコーポレイテッド | Hpv16−e7ペプチド/mhc複合体を標的化する構築物およびその使用 |
US11267899B2 (en) | 2015-05-13 | 2022-03-08 | Zumutor Biologics Inc. | Afucosylated protein, cell expressing said protein and associated methods |
JP2018535655A (ja) | 2015-09-29 | 2018-12-06 | アムジエン・インコーポレーテツド | Asgr阻害剤 |
EP3426688A1 (en) | 2016-03-08 | 2019-01-16 | Innate Pharma | Siglec neutralizing antibodies |
WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
WO2018102746A1 (en) | 2016-12-02 | 2018-06-07 | Rigel Pharmaceuticals, Inc. | Antigen binding molecules to tigit |
SG10202108135VA (en) | 2016-12-16 | 2021-09-29 | Merck Patent Gmbh | Methods for the use of galectin 3 binding protein detected in the urine for monitoring the severity and progression of lupus nephritis |
US11680101B2 (en) | 2017-01-27 | 2023-06-20 | Kymab Limited | Anti-OPG antibodies |
AU2018290856A1 (en) | 2017-06-28 | 2020-01-02 | Regeneron Pharmaceuticals, Inc. | Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof |
WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
WO2019028555A1 (en) | 2017-08-09 | 2019-02-14 | University Of Saskatchewan | HER3 BINDING AGENTS AND USES THEREOF |
KR101895228B1 (ko) | 2017-08-23 | 2018-10-30 | 대한민국 | 중동호흡기증후군 코로나바이러스의 스파이크 단백질에 대한 단일클론항체 및 이의 용도 |
IL310960A (en) | 2017-09-22 | 2024-04-01 | Wuxi Biologics Ireland Ltd | New bispecific polypeptide complexes |
GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
AU2020340881A1 (en) | 2020-04-02 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments |
WO2021203053A1 (en) * | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
BR112022020706A2 (pt) * | 2020-04-14 | 2022-11-29 | Vir Biotechnology Inc | Anticorpos contra sars-cov-2 e métodos de uso dos mesmos |
EP4146690A1 (en) * | 2020-05-08 | 2023-03-15 | VIR Biotechnology, Inc. | Antibodies against sars-cov-2 |
WO2021247925A1 (en) * | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
TW202207983A (zh) * | 2020-06-12 | 2022-03-01 | 美商維爾生物科技股份有限公司 | 用於sars-cov-2感染的抗體療法 |
CN112062859B (zh) * | 2020-07-24 | 2022-08-09 | 沣潮医药科技(上海)有限公司 | 用于病原体清除的嵌合抗原受体及其应用 |
-
2021
- 2021-02-25 DK DK21159353.8T patent/DK3872091T3/da active
- 2021-02-25 IL IL295801A patent/IL295801A/en unknown
- 2021-02-25 US US17/185,340 patent/US11168128B2/en active Active
- 2021-02-25 RS RS20230783A patent/RS64645B1/sr unknown
- 2021-02-25 LT LTEP21159353.8T patent/LT3872091T/lt unknown
- 2021-02-25 KR KR1020227006804A patent/KR20220164465A/ko not_active Application Discontinuation
- 2021-02-25 SG SG11202110145SA patent/SG11202110145SA/en unknown
- 2021-02-25 TW TW110106804A patent/TW202146442A/zh unknown
- 2021-02-25 MX MX2022010537A patent/MX2022010537A/es unknown
- 2021-02-25 PT PT211593538T patent/PT3872091T/pt unknown
- 2021-02-25 PL PL21159353.8T patent/PL3872091T3/pl unknown
- 2021-02-25 JP JP2022551302A patent/JP7275405B2/ja active Active
- 2021-02-25 HU HUE21159353A patent/HUE062777T2/hu unknown
- 2021-02-25 HR HRP20231031TT patent/HRP20231031T1/hr unknown
- 2021-02-25 CA CA3158752A patent/CA3158752C/en active Active
- 2021-02-25 AU AU2021227687A patent/AU2021227687B2/en active Active
- 2021-02-25 WO PCT/US2021/019531 patent/WO2021173753A1/en active Application Filing
- 2021-02-25 ES ES21159353T patent/ES2954629T3/es active Active
- 2021-02-25 MA MA56074A patent/MA56074B1/fr unknown
- 2021-02-25 SI SI202130058T patent/SI3872091T1/sl unknown
- 2021-02-25 EP EP23175785.7A patent/EP4245373A3/en active Pending
- 2021-02-25 BR BR112022017048A patent/BR112022017048A2/pt unknown
- 2021-02-25 EP EP21159353.8A patent/EP3872091B1/en active Active
- 2021-02-25 FI FIEP21159353.8T patent/FI3872091T3/fi active
- 2021-07-23 US US17/384,665 patent/US11479599B2/en active Active
-
2022
- 2022-08-26 CL CL2022002335A patent/CL2022002335A1/es unknown
- 2022-09-14 US US17/932,147 patent/US20230331821A1/en active Pending
- 2022-09-20 CO CONC2022/0013525A patent/CO2022013525A2/es unknown
- 2022-10-07 JP JP2022162148A patent/JP2023009046A/ja active Pending
-
2023
- 2023-05-22 AU AU2023203201A patent/AU2023203201A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022017048A2 (pt) | Anticorpos contra sars-cov-2 e métodos para usar os mesmos | |
BR112022015374A2 (pt) | Anticorpos contra sars-cov-2 e métodos de uso dos mesmos | |
BR112022022523A2 (pt) | Anticorpos contra sars-cov-2 | |
BR112022020706A2 (pt) | Anticorpos contra sars-cov-2 e métodos de uso dos mesmos | |
EA202090364A1 (ru) | Антитела с функциональными доменами в области изгиба между вариабельным и константным доменами | |
CL2023000705A1 (es) | Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno | |
BR112019008634A2 (pt) | anticorpos anti-pd-l1 e variantes | |
BR112017003194A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, vacina, vaso ou dispositivo de injeção, e, métodos para antagonizar lag3 em um paciente humano que necessita do mesmo, para tratamento de um câncer em um indivíduo para administrar o anticorpo, o fragmento, a composição, o polipeptídeo, a vacina, o vetor ou o polinucleotídeo de ligação ao antígeno a um indivíduo, para produção de um anticorpo ou de um fragmento de ligação ao antígeno do mesmo ou polipeptídeo e para detectar a presença de um peptídeo lag3 ou de um fragmento do mesmo em uma amostra. | |
BR112016013347A2 (pt) | anticorpo monoclonal humano neutralizante anti-il-33 | |
AR103488A1 (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
BR112014021081A2 (pt) | anticorpos para a metaloproteinase da matriz 9 | |
WO2019014328A3 (en) | AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF | |
BR112013004579A2 (pt) | proteína de ligação à mmp9, ácido nucleico, vetor, célula, composição farmacêutica e seu uso bem como método de detecção da expressão mmp9 | |
BR112022000216A2 (pt) | Anticorpos direcionados a dll3 e usos dos mesmos | |
BR112019005129A2 (pt) | anticorpos anti-pd-1 | |
BR112015030892A2 (pt) | Proteína de ligação ao antígeno, anticorpo monoclonal, ácido nucleico recombinante, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma proteína de ligação ao antígeno ou anticorpo humanizado, e, método para produzir uma proteína de ligação ao antígeno | |
BR112021026133A2 (pt) | Anticorpo anti-cd24 e usos do mesmo | |
PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
BR112021016272A2 (pt) | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos | |
BR112016015678A2 (pt) | Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso | |
BR112022012474A2 (pt) | Anticorpo anti-lilrb1, fragmento de ligação ao antígeno do mesmo, composição farmacêutica que compreende os mesmos, uso do dito anticorpo para tratar ou prevenir um câncer, método de preparar o dito anticorpo, molécula de ácido nucleico e vetor e célula recombinantes. | |
WO2022067269A3 (en) | Antibodies against sars-cov-2 | |
BR112021016398A2 (pt) | Anticorpos cd33 e métodos de uso dos mesmos para tratar o câncer | |
BR112022006534A2 (pt) | Anticorpos anti-nogo-a | |
MX2023005654A (es) | Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza. |